MOSCOW (Sputnik) – The Russian Direct Investment Fund (RDIF) announced on Friday that it reached an agreement with India’s pharmaceutical company Hetero on producing over 100 million doses of Russia’s coronavirus vaccine Sputnik V per year in India.
“RDIF … and Hetero, one of India’s leading generic pharmaceutical companies (through its biologics arm “Hetero Biopharma”) have agreed to produce in India over 100 million doses per year of the world’s first registered vaccine against the novel coronavirus infection – Sputnik V,” RDIF said in a press release, published in the Twitter account of the vaccine.
Production is expected to start at the beginning of 2021.
Hetero Labs Limited Director for International Marketing B. Murali Krishna Reddy noted that the company was pleased to cooperate with RDIF as a manufacturing partner for the “most anticipated” vaccine.
In August, Sputnik V, developed by the Gamaleya research institute and produced in cooperation with RDIF, became the world’s first registered vaccine against COVID-19.
According to the results of the second interim analysis of the clinical trials data, the vaccine has proven to be 91.4 percent effective 28 days after the injection of the first dose and 95 percent effective 42 days after the injection of the first dose.